Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

PS230005 Control-IQ 1.5 Post-Approval Study

NCT: NCT06717451 · COMPLETED

NCT IDNCT06717451
StatusCOMPLETED
Start Date2025-01-30
Completion2026-08-10
SponsorTandem Diabetes Care, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to \<6 years old. Participants will use Control-IQ technology v1.5 for 12 months in the real-world setting.

Frequently Asked Questions

What is PS230005 Control-IQ 1.5 Post-Approval Study?

PS230005 Control-IQ 1.5 Post-Approval Study is a clinical trial registered under NCT06717451. Current status: COMPLETED.

What is the status of NCT06717451?

The current status of NCT06717451 (PS230005 Control-IQ 1.5 Post-Approval Study) is: COMPLETED.

When did PS230005 Control-IQ 1.5 Post-Approval Study start?

PS230005 Control-IQ 1.5 Post-Approval Study started on 2025-01-30.

Related Devices

K200467Control-IQ TechnologyTandem Diabetes Care, Inc. K232382Control-IQ TechnologyTandem Diabetes Care, Inc. K243823Control-IQ+ technologyTandem Diabetes Care, Inc. K250798Control-IQ+ technologyTandem Diabetes Care, Inc. K260429Control-IQ+ technologyTandem Diabetes Care, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑